METTL3/YTHDF1 drives M1 macrophage polarization and aggravates ulcerative colitis progression by regulating m6A

Tian Pu1, Ranran Feng2, Chunru Wang2

  • 1Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, Henan, China. iputian0209@163.com.

PubMed
Abstract

Insights

Serine protease inhibitor B5 (SerpinB5) promotes ulcerative colitis (UC) by enhancing M1 macrophage polarization through the METTL3/m6A/YTHDF1 and FBXO32/NF-κB pathways. Targeting SerpinB5 offers a promising therapeutic strategy for UC.

Area of Science:

  • Immunology
  • Gastroenterology
  • Molecular Biology

Background:

  • Ulcerative colitis (UC) is a chronic intestinal inflammation where macrophages play a key role.
  • Serine protease inhibitor B5 (SerpinB5) influences macrophage phenotype, but its role in UC remains unclear.

Purpose of the Study:

  • To investigate the role and mechanism of SerpinB5 in ulcerative colitis (UC).
  • To explore the potential of SerpinB5 as a therapeutic target for UC.

Main Methods:

  • Analysis of SerpinB5 expression in UC patients and models.
  • In vitro and in vivo UC models using TNF-α stimulation and DSS administration.
  • Assessment of macrophage polarization, inflammation, apoptosis, and senescence.
  • Investigation of the METTL3/m6A/YTHDF1 and FBXO32/NF-κB pathways.

Main Results:

  • SerpinB5 expression is elevated in UC.
  • SerpinB5 silencing reduced inflammation, apoptosis, senescence, and M1 macrophage polarization in UC models.
  • SerpinB5 positively regulates the NF-κB pathway via FBXO32.
  • METTL3 enhances SerpinB5 mRNA stability through m6A modification dependent on YTHDF1.

Conclusions:

  • The METTL3/YTHDF1 axis promotes UC progression by enhancing M1 macrophage polarization via SerpinB5 mRNA m6A modification and the FBXO32/NF-κB pathway.
  • SerpinB5 represents a potential therapeutic target for ulcerative colitis.